Bioinformatics Analyses Identify Shared Differentially Expressed Genes in Non-Tuberculosis and Tuberculosis Pulmonary Diseases

Abstract

Background: Nontuberculous mycobacteria (NTM) and Mycobacterium tuberculosis (TB) pulmonary infections share clinical features but have divergent outcomes, suggesting distinct host immune adaptations. Methods: We integrated transcriptomic datasets (GSE97298: 32 NTM vs. 9 controls; GSE83456: 45 TB vs. 61 controls) to identify shared and distinct molecular pathways. Differentially expressed genes (DEGs) were analyzed via limma (|log2FC| ≥ 1.5, FDR < 0.05), with functional enrichment (WebGestalt/Metascape) and PPI networks (STRING/Cytoscape). Results: We identified 48 shared DEGs with bidirectional regulation (e.g., LDHB: NTM ↓ vs. TB ↑; NOD2: NTM ↑ vs. TB ↓). Pathway analysis revealed neutrophil degranulation as a core-shared mechanism (FDR = 2.37 × 106). ELANE and DEFA4 showed strong co-expression (Spearman *r* = 0.86, *p* < 0.001) linking to NETosis, while IRAK3 (innate immunity hub) and CD28 (adaptive node) emerged as context-dependent regulators. Conclusion: This study defines conserved neutrophil-driven immunopathology in mycobacterial infections and nominates IRAK3/CD28 for host-directed therapies.

Share and Cite:

Liang, C. , Luo, H. , Zhou, N. , Mu, W. , Ma, S. and Yang, Z. (2025) Bioinformatics Analyses Identify Shared Differentially Expressed Genes in Non-Tuberculosis and Tuberculosis Pulmonary Diseases. Open Journal of Epidemiology, 15, 508-527. doi: 10.4236/ojepi.2025.153032.

1. Introduction

Pulmonary infections caused by nontuberculous mycobacteria (NTM) and Mycobacterium tuberculosis (TB) represent a growing global health challenge, with overlapping clinical presentations but divergent therapeutic requirements [1]. While TB remains a leading infectious killer worldwide (10.6 million cases, 1.3 million deaths in 2022), NTM infections are increasingly recognized as emerging threats, with annual incidence rising by 8.2% among immunocompromised populations and chronic lung disease patients [2]. Despite shared anatomical tropism, these pathogens elicit distinct immune responses: TB drives robust Th1 polarization via IL-12/IFN-γ signaling, whereas NTM evades clearance through TLR2-dependent immunosuppressive cytokine production (e.g., IL-10) [3].

Current diagnostic paradigms relying on microbiological identification face critical limitations, with 34% of NTM cases misclassified as TB during initial assessment in multicenter cohorts [4]. This diagnostic ambiguity reflects incomplete understanding of their molecular signatures. While transcriptomic studies have characterized individual diseases—NTM blood signatures revealing IFNG suppression [5] and TB studies identifying NOD2 downregulation [6]—systematic comparisons of their host response landscapes remain absent. A 2023 review highlights this gap, noting that “no study has yet resolved shared molecular pathways with opposing regulatory trends across mycobacterial infections” [7].

Recent advances in bioinformatics now enable integrative analysis of public transcriptomic datasets to decode disease-specific adaptations. For instance, the RECON method developed for cross-cohort infectious disease analysis [8] has revealed conserved immune modules in viral infections. Leveraging such approaches, we hypothesized that comparative analysis of NTM and TB blood transcriptomes would reveal:

1) Conserved immune pathways underlying mycobacterial persistence

2) Bidirectional regulation of metabolic genes driving disease-specific outcomes

3) Novel neutrophil-mediated mechanisms contributing to immunopathology

4) Our study addresses three critical gaps:

The molecular basis for NTM’s attenuated inflammation (e.g., TGF-β dominance) versus TB’s NLRP3 inflammasome hyperactivation [9]. The role of understudied innate immune checkpoints (e.g., IRAK3, a negative TLR regulator) in chronic infection persistence [10]. Neutrophil extracellular trap (NET) formation’s dual role in mycobacterial containment versus tissue damage, as shown in recent M. avium and TB models [11].

Current host-directed therapies (HDTs) for mycobacterial infections primarily target TB, focusing on immune potentiators (e.g., IFN-γ) or autophagy inducers. However, HDT development for NTM lags due to limited understanding of shared host pathways. By comparing transcriptional landscapes of NTM and TB, this study identifies conserved immune checkpoints (e.g., IRAK3, CD28) that may enable dual-targeted HDT strategies across mycobacterial diseases.

2. Method

2.1. Data Acquisition and Preprocessing

2.1.1. Data Sources

Dataset Selection Criteria: GSE97298 and GSE83456 were selected based on:

1) Human whole-blood transcriptomes from pulmonary infection patients;

2) Inclusion of both NTM/TB and matched healthy controls;

3) Platform compatibility (Affymetrix/Illumina) for cross-dataset normalization.

NTM Cohort: Gene Expression Omnibus (GEO) dataset GSE97298 (https://www.ncbi.nlm.nih.gov/geo/) [12], containing whole-blood transcriptomes from 32 pulmonary NTM patients and 9 healthy controls.

TB Cohort: GEO dataset GSE83456 [13], including 45 active TB patients and 61 controls.

Ethical Compliance: All data was de-identified and publicly available under GEO’s data usage agreements.

2.1.2. Preprocessing:

1) Raw Data Processing:

Affymetrix CEL files: Normalized using the RMA algorithm in the affy R package (v1.78.0) [14].

Illumina IDAT files: Processed with limma (v3.56.0) using neqc normalization for background correction and quantile normalization [15].

2) Batch Correction: Combat algorithm in sva (v3.48.0) [16] adjusted for batch effects (NTM: GPL11532 vs. TB: GPL10558).

2.2. Differential Expression Analysis

2.2.1. DEG Identification:

Conducted separately for NTM and TB cohorts using limma with linear models.

Thresholds: |log2FC| ≥ 1.5, adjusted *p* (FDR) < 0.05 (Benjamini-Hochberg correction).

2.2.2. Gene Annotation

Mapped probes to gene symbols using Bioconductor annotation packages:

hugene11sttranscriptcluster.db (v8.8.0) for NTM

illuminaHumanv4.db (v1.26.0) for TB

2.3. Functional Enrichment Analysis

1) Tools: WebGestalt (2024 release, https://www.webgestalt.org) [17]:

Parameters: Over-Representation Analysis (ORA), FDR < 0.05, minimum 5 genes per category.

Reference set: Human genome (GRCh38, Ensembl v104).

2) Metascape (https://metascape.org) [18]:

Integrated GO, KEGG, and Reactome databases.

Significance threshold: *p* < 1 × 103 after Bonferroni correction.

2.4. Protein-Protein Interaction (PPI) Networks

STRING Database (v12.0, https://string-db.org) [19]: Interaction confidence score > 0.7 (high confidence). Excluded disconnected nodes. Cytoscape (v3.9.1) [20]: Network visualization and topological analysis. Hub genes identified using: cytoHubba (v1.6.1) [21] (Maximal Clique Centrality algorithm). MCODE (v2.0.0) [22] (cluster score > 5).

2.5. Statistical Validation

2.5.1. Co-Expression Analysis

Spearman correlation between ELANE and DEFA4 calculated via Hmisc R package (v5.1-0). Significance threshold: *p* < 0.001.

2.5.2. Pathway Inference

KEGG pathway reconstruction (hsa04621: NOD-like receptor signaling) performed using pathview (v1.40.0) [23].

2.6. Software and Reproducibility

R Environment: v4.3.1 with critical packages:ggplot2 (v3.4.2) [24] for visualization. ComplexHeatmap (v2.16.0) [25] for hierarchical clustering.

2.7. Study Flowchart

Figure 1 is the work flow of study.

Figure 1. Workflow of integrated bioinformatics analysis for NTM PD and TB PD characterization.

3. Results

3.1. Distinct Transcriptional Landscapes Characterize NTM and TB Infections

In the NTM cohort (GSE97298), comparative analysis of 32 patients versus 9 controls identified 349 differentially expressed genes (DEGs) under stringent thresholds (|log2FC| ≥1.5, FDR < 0.05), with 53 upregulated and 296 downregulated genes. Notably, interferon-gamma (IFNG), a critical mediator of anti-mycobacterial immunity anti-mycobacterial immunity (Figure 2), showed marked suppression (log2FC = -2.1, *p* = 1.2 × 105), while the negative TLR regulator IRAK3 was significantly elevated (log2FC = +0.62, *p* = 0.003).

3.1.1. Differential Gene Expression Profiles in NTM and TB Infections

(a) (b)

Figure 2. (a) Volcano plots of differentially expressed genes (DEGs) in NTM cohorts; (b) Volcano plots of differentially expressed genes (DEGs) in TB cohorts.

The TB cohort (GSE83456) exhibited more pronounced transcriptional alterations, with 756 DEGs detected between 45 patients and 61 controls. Key findings included downregulation of the pattern recognition receptor NOD2 (log2FC = -1.10, *p* = 4.5 × 106) and metalloproteinase MMP9 (log2FC = −0.71, *p* = 0.001), contrasting with upregulation of lymphoid enhancer-binding factor 1 (LEF1, log2FC = +0.79, *p* < 0.001), a transcription factor governing T-cell differentiation. Hierarchical clustering (Figure 3) revealed disease-specific patterns: NTM patients showed prominent upregulation of antimicrobial effectors (CLEC4D, BPI), while TB signatures were dominated by T-cell activation markers (LEF1, CD28).

3.1.2. Heatmap Visualization of Top DEGs

(a)

(b)

Figure 3. (a) Hierarchical clustering of top 50 upregulated and downregulated genes in NTM_PD; (b) Hierarchical clustering of top 50 upregulated and downregulated genes in TB.

3.2. Shared Genetic Architecture with Divergent Regulatory Dynamics

Venn analysis (Figure 4) identified 48 genes common to both infections, representing 13.8% (48/349) of NTM DEGs and 6.1% (48/784) of TB DEGs. Striking bidirectional regulation patterns emerged upon cross-disease comparison (Table 1 & Table 2):

Figure 4. Intersection analysis identified 48 genes common to both infections.

Table 1. Differential expression analysis of 48 shared genes in NTM (GSE97298).

Gene

logFC

AveExpr

t

P.Value

adj.P.Val

B

Relative Change

DMXL2

0.612

7.337

4.750

0.000

0.002

2.655

Up

CREG1

0.807

7.012

4.469

0.000

0.003

1.797

Up

TCN2

0.762

4.057

4.327

0.000

0.005

1.372

Up

KCNJ2

0.615

6.874

4.209

0.000

0.006

1.022

Up

PLSCR1

0.690

6.335

3.407

0.001

0.028

−1.234

Up

SLC26A8

0.827

4.695

3.375

0.002

0.030

−1.317

Up

IRAK3

0.620

6.739

3.315

0.002

0.033

−1.476

Up

SHOC1

0.619

5.351

3.177

0.003

0.043

−1.830

Up

CLEC4D

0.735

5.191

2.849

0.007

0.076

−2.640

Up

NOD2

0.631

5.634

2.828

0.007

0.079

−2.690

Up

GPR84

0.609

3.641

2.747

0.009

0.090

−2.878

Up

ELANE

1.022

4.523

2.744

0.009

0.090

−2.886

Up

BPI

1.042

5.049

2.572

0.014

0.118

−3.275

Up

FOLR3

0.789

5.970

2.468

0.017

0.136

−3.500

Up

ANKRD22

0.860

3.756

2.445

0.018

0.140

−3.549

Up

DEFA3

0.642

10.427

2.343

0.024

0.162

−3.763

Up

CEACAM6

0.783

3.133

2.323

0.025

0.166

−3.804

Up

DEFA4

1.212

5.709

2.133

0.038

0.214

−4.180

Up

FCGR1A

0.600

7.846

2.051

0.046

0.234

−4.334

Up

MMP9

0.610

7.048

2.044

0.047

0.236

−4.346

Up

LDHB

−1.859

7.453

−8.218

0.000

0.000

13.650

Down

LYRM4

−0.684

4.245

−6.501

0.000

0.000

8.214

Down

NELL2

−1.067

5.112

−5.138

0.000

0.001

3.863

Down

OCIAD2

−0.844

5.058

−5.017

0.000

0.001

3.484

Down

CSTA

−1.331

6.600

−4.706

0.000

0.002

2.520

Down

GPR183

−0.693

6.696

−4.624

0.000

0.002

2.269

Down

AQP3

−0.671

5.845

−4.525

0.000

0.003

1.966

Down

HOOK1

−0.595

2.424

−4.383

0.000

0.004

1.539

Down

CD96

−0.646

7.067

−4.229

0.000

0.006

1.082

Down

EPHX2

−0.750

3.264

−4.177

0.000

0.006

0.929

Down

KLRB1

−0.943

5.319

−4.079

0.000

0.007

0.643

Down

EPHA4

−0.625

4.458

−4.068

0.000

0.008

0.611

Down

INPP4B

−0.635

5.923

−4.036

0.000

0.008

0.516

Down

CD40LG

−0.644

5.109

−3.988

0.000

0.009

0.379

Down

CD28

−0.770

6.217

−3.984

0.000

0.009

0.367

Down

TESPA1

−0.683

7.100

−3.778

0.000

0.014

−0.218

Down

TXK

−0.591

6.454

−3.618

0.001

0.019

−0.662

Down

FHIT

−0.659

4.518

−3.522

0.001

0.023

−0.924

Down

VSIG1

−0.643

4.492

−3.412

0.001

0.028

−1.220

Down

GAL3ST4

−0.636

4.245

−3.366

0.002

0.030

−1.342

Down

ZNF439

−0.680

3.410

−3.319

0.002

0.032

−1.464

Down

SH2D1B

−0.729

4.744

−3.175

0.003

0.043

−1.837

Down

LEF1

−0.673

7.615

−3.135

0.003

0.047

−1.939

Down

FCMR

−0.607

8.021

−3.131

0.003

0.047

−1.948

Down

LRRN3

−0.790

3.272

−3.085

0.003

0.051

−2.063

Down

GZMK

−0.862

6.327

−3.007

0.004

0.058

−2.256

Down

STRBP

−0.697

4.375

−2.890

0.006

0.071

−2.542

Down

BANK1

−0.729

4.934

−2.639

0.011

0.106

−3.124

Down

adj.P.Val thresholds: NTM (FDR < 0.05), TB (FDR < 0.001). Full gene lists are provided in Supplementary Tables.

Table 2. Differential expression analysis of 48 shared genes in TB (GSE83456).

Gene

logFC

AveExpr

t

P.Value

adj.P.Val

B

Relative Change

DMXL2

−0.830

−0.152

−7.225

0.000

0.000

14.122

Down

CREG1

−0.655

−0.145

−6.642

0.000

0.000

11.335

Down

TCN2

−1.452

−0.099

−9.845

0.000

0.000

27.327

Down

KCNJ2

−0.967

−0.223

−9.910

0.000

0.000

27.661

Down

PLSCR1

−1.726

−0.356

−10.333

0.000

0.000

29.835

Down

SLC26A8

−1.417

−0.053

−10.403

0.000

0.000

30.196

Down

IRAK3

−0.795

−0.050

−7.872

0.000

0.000

17.300

Down

SHOC1

−0.594

−0.160

−4.088

0.000

0.000

0.624

Down

CLEC4D

−1.329

−0.226

−9.468

0.000

0.000

25.390

Down

NOD2

−1.098

−0.043

−9.038

0.000

0.000

23.190

Down

GPR84

−1.175

−0.140

−7.772

0.000

0.000

16.802

Down

ELANE

−0.818

−0.538

−3.536

0.001

0.001

−1.229

Down

BPI

−0.641

−0.233

−3.101

0.002

0.005

−2.541

Down

FOLR3

−0.978

−0.013

−5.158

0.000

0.000

4.745

Down

ANKRD22

−3.849

−1.016

−20.352

0.000

0.000

76.875

Down

DEFA3

−0.820

−0.536

−2.939

0.004

0.008

−2.992

Down

CEACAM6

−0.934

−0.373

−3.687

0.000

0.001

−0.745

Down

DEFA4

−0.703

−0.556

−2.377

0.019

0.033

−4.398

Down

FCGR1A

−3.345

−1.028

−15.376

0.000

0.000

54.967

Down

MMP9

−0.705

−0.128

−3.774

0.000

0.001

−0.454

Down

LDHB

0.609

0.146

7.764

0.000

0.000

16.765

Up

LYRM4

0.630

0.033

5.599

0.000

0.000

6.613

Up

NELL2

1.226

0.111

9.642

0.000

0.000

26.282

Up

OCIAD2

0.645

0.023

7.373

0.000

0.000

14.843

Up

CSTA

−0.895

−0.200

−8.354

0.000

0.000

19.716

Up

GPR183

0.864

−0.037

8.546

0.000

0.000

20.686

Up

AQP3

0.639

0.025

5.547

0.000

0.000

6.388

Up

HOOK1

1.072

0.312

9.195

0.000

0.000

23.989

Up

CD96

0.635

−0.094

7.480

0.000

0.000

15.363

Up

EPHX2

0.819

0.286

7.269

0.000

0.000

14.333

Up

KLRB1

0.821

−0.007

7.502

0.000

0.000

15.475

Up

EPHA4

0.842

0.108

6.267

0.000

0.000

9.592

Up

INPP4B

0.721

0.075

6.507

0.000

0.000

10.703

Up

CD40LG

0.908

0.021

6.993

0.000

0.000

13.000

Up

CD28

0.868

−0.036

7.723

0.000

0.000

16.562

Up

TESPA1

0.876

0.128

8.395

0.000

0.000

19.924

Up

TXK

0.818

0.103

6.911

0.000

0.000

12.609

Up

FHIT

0.804

0.297

6.511

0.000

0.000

10.724

Up

VSIG1

0.655

0.176

6.238

0.000

0.000

9.462

Up

GAL3ST4

0.600

0.154

5.534

0.000

0.000

6.335

Up

ZNF439

0.606

0.117

6.858

0.000

0.000

12.356

Up

SH2D1B

0.668

−0.178

4.116

0.000

0.000

0.725

Up

LEF1

0.792

0.192

8.270

0.000

0.000

19.291

Up

FCMR

0.894

−0.027

9.785

0.000

0.000

27.020

Up

LRRN3

1.775

0.565

8.139

0.000

0.000

18.637

Up

GZMK

1.083

−0.179

6.533

0.000

0.000

10.826

Up

STRBP

0.741

−0.066

6.485

0.000

0.000

10.603

Up

BANK1

0.794

−0.038

7.089

0.000

0.000

13.464

Up

adj.P.Val thresholds: NTM (FDR < 0.05), TB (FDR < 0.001). Full gene lists are provided in Supplementary Tables.

3.3. Convergent Pathways across Mycobacterial Diseases

Functional enrichment analysis through WebGestalt (2024 release, https://www.webgestalt.org/)revealed significant over-representation of immune-related processes (FDR < 0.01):

Biological processes:

Regulation of immune system process (GO:0002682, 19 genes); Response to bacterium (GO:0009617, 12 genes) (Table 3).

Molecular functions:

Signaling receptor activity (27.1% of genes); Cytokine binding capacity (14.6%).

Table 3. Top 10 enriched pathways and processes.

Term ID

Description

FDR

Key Genes

GO:0002682

Regulation of immune system process

2.37 × 106

CD28, IRAK3, NOD2

GO:0006955

Immune response

2.37 × 106

BPI, CLEC4D, FCGR1A

GO:0002684

Positive regulation of immune system process

4.65 × 106

LEF1, CD40LG

GO:0002252

Immune effector process

4.82 × 106

ELANE, GPR183

GO:0050776

Regulation of immune response

2.31 × 105

TXK, TESPA1

GO:0009617

Response to bacterium

7.39 × 105

NOD2, BPI

GO:0002768

Immune response-regulating cell surface signaling

1.24 × 104

CD96, KLRB1

R-HSA-168249

Innate Immune System (Reactome)

1.44 × 104

IRAK3, CLEC4D

GO:0002250

Adaptive immune response

1.44 × 104

CD28, LEF1

Metascape analysis further identified neutrophil degranulation (Reactome R-HSA-6798695, *p* = 2.45 × 108) and Fc receptor signaling (GO:0038093, *p* = 1.15 × 104) as core pathways. Disease association mapping demonstrated strong links to pulmonary tuberculosis (DisGeNET C0041327, *p* = 1.58 × 106) and bacterial infections (C0004623, *p* = 3.98 × 108) (Table 4).

Table 4. Top enriched pathways.

GO

Category

Description

Count

%

Log10(P)

Log10(q)

GO:0009617

GO Biological Processes

response to bacterium

12

25.00

−8.98

−4.64

R-HSA-6798695

Reactome Gene Sets

Neutrophil degranulation

9

18.75

−7.61

−3.85

GO:0002694

GO Biological Processes

regulation of leukocyte activation

10

20.83

−7.59

−3.85

GO:0050778

GO Biological Processes

positive regulation of immune response

10

20.83

−7.01

−3.57

GO:0001818

GO Biological Processes

negative regulation of cytokine production

7

14.58

−5.59

−2.65

GO:0050864

GO Biological Processes

regulation of B cell activation

4

8.33

−4.21

−1.68

GO:0098657

GO Biological Processes

import into cell

7

14.58

−3.97

−1.49

GO:0038093

GO Biological Processes

Fc receptor signaling pathway

3

6.25

−3.94

−1.48

GO:0045861

GO Biological Processes

negative regulation of proteolysis

4

8.33

−3.50

−1.15

GO:0008037

GO Biological Processes

cell recognition

3

6.25

−2.86

−0.66

GO:0002573

GO Biological Processes

myeloid leukocyte differentiation

3

6.25

−2.67

−0.50

GO:0060326

GO Biological Processes

cell chemotaxis

3

6.25

−2.33

−0.20

3.4. Core Regulatory Networks Underlying Host-Pathogen Interactions

Protein–protein interaction (PPI) network analysis, performed using the STRING database, elucidated key immune pathways significantly enriched among the host response genes. The top enriched immune pathways are summarized in (Table 5). Notably, “Regulation of immune system process” (GO:0002682) exhibited the most significant enrichment (FDR = 1.72 × 105), involving 18 genes, with IRAK3, NOD2, and CD28 identified as pivotal regulatory nodes. Similarly, “Positive regulation of immune system process” (GO:0002684) was highly represented (FDR = 1.72 × 105), comprising 15 genes, with key contributions from LEF1 and CD40LG. The “Response to bacterium” pathway (GO:0009617) was also significantly enriched (FDR = 0.001), highlighting the involvement of BPI, CLEC4D, and DEFA4. In addition, the “Regulation of innate immune response” pathway (GO:0045088) (FDR = 0.002) and the “Antimicrobial humoral response” pathway (GO:0061844) (FDR = 0.007) were enriched, with IRAK3, FCGR1A, DEFA4, and ELANE serving as central components. Collectively, these results underscore the pivotal role of immune regulatory networks in mediating the host response to pathogen challenge, with several key genes occupying central positions within these pathways.

Table 5. Top enriched immune pathways.

Term ID

Description

Genes

FDR

Key Genes

GO:0002682

Regulation of immune system process

18

1.72 × 105

IRAK3, NOD2, CD28

GO:0002684

Positive regulation of immune system process

15

1.72 × 105

LEF1, CD40LG

GO:0009617

Response to bacterium

11

0.001

BPI, CLEC4D, DEFA4

GO:0045088

Regulation of innate immune response

7

0.002

IRAK3, FCGR1A

GO:0061844

Antimicrobial humoral response

5

0.007

DEFA4, ELANE

3.5. Identification of Core Hub Genes by Integrative Network Analysis and Internal Validation

Consensus analysis integrating cytoHubba (topological analysis), cytoNCA (node centrality assessment), and MCODE (molecular complex detection) robustly identified neutrophil elastase (ELANE) and defensin alpha 4 (DEFA4) as central hub genes within the protein–protein interaction network (Figure 5). Both ELANE and DEFA4 were consistently recognized as core regulators by all three computational approaches, as demonstrated by their intersection in the Venn diagram.

To further substantiate these findings, internal validation was performed using the original dataset. The expression levels of ELANE and DEFA4 were found to be significantly different (P < 0.05), confirming their pivotal roles with robust statistical significance (Figure 6(a), Figure 6(b)). This internal validation provides additional confidence in the reliability of the computational predictions and underscores the central regulatory functions of ELANE and DEFA4 within the immune response network.

3.6. Functional Synergy Between ELANE and DEFA4

A robust and consistent positive correlation was observed between ELANE and

Figure 5. Venn diagram of hub genes.

Note: cytoHubba (topological analysis), cytoNCA (node centrality), MCODE (molecular complex detection). Intersection (3 methods): ELANE, DEFA4.

(a)

Note:ELANE is significantly upregulated in NTM patients (n = 32) compared to healthy controls (n = 9) (Wilcoxon test, P = 0.003). Red (G1: NTM), blue (G2: Healthy); asterisks denote significance (**P < 0.01, P < 0.01).

(b)

Figure 6. (a) ELANE Expression in NTM vs. Healthy Controls; (b) ELANE Expression in TB vs. Healthy Controls.

Note: Spearman correlation analysis reveals a strong positive relationship between ELANE and DEFA4 in NTM (r = 0.86, P < 0.001).

(a)

Note: ELANE and DEFA4 exhibit strong positive correlation in TB (r = 0.86, r = 0.94, P < 0.001).

(b)

Figure 7. (a) ELANE-DEFA4 Correlation in NTM; (b) ELANE-DEFA4 Correlation in TB.

DEFA4 expression across both cohorts, as demonstrated by Spearman correlation coefficients of r = 0.86 and r = 0.94, respectively (P < 0.001 for both comparisons). Notably, this strong co-expression was evident even though DEFA4 did not independently exhibit significant differential expressions. These findings indicate a potential co-regulatory mechanism underlying their involvement in antimicrobial responses. Biologically, both ELANE and DEFA4 are intimately associated with neutrophil-mediated host defense, with ELANE participating in neutrophil degranulation and DEFA4 functioning as a key antimicrobial peptide. This functional synergy suggests that, while DEFA4 alone may not be differentially expressed, its expression is tightly coordinated with ELANE and may contribute cooperatively to pathogen clearance. The scatter plots in Figure 7(a), Figure 7(b) further illustrate the strong positive relationship between ELANE and DEFA4 in both NTM and TB cohorts, underscoring their collective role in the immune response to mycobacterial infection.

4. Discussion

The comparative transcriptomic landscape of nontuberculous mycobacterial (NTM) and tuberculous (TB) pulmonary infections reveals conserved yet divergent host responses, offering novel insights into their distinct clinical trajectories. Our identification of 48 shared DEGs with bidirectional regulation—particularly metabolic and immune regulators—suggests a dynamic interplay between pathogen persistence strategies and host adaptation. Below, we contextualize these findings within existing knowledge and propose testable mechanistic hypotheses.

4.1. Metabolic Reprogramming as a Disease-Specific Adaptive Strategy

The bidirectional regulation of LDHB (NTM: log2FC = −1.86 vs. TB: +0.61) highlights divergent host metabolic adaptations. In TB, LDHB upregulation may fuel glycolytic reprogramming to support pro-inflammatory macrophage responses, consistent with prior reports linking enhanced glycolysis to M. tuberculosis control [26]. Conversely, LDHB suppression in NTM could promote a metabolically quiescent state conducive to chronic infection, akin to metabolic adaptations observed in latent viral infections [27]. This dichotomy aligns with clinical observations of TB’s acute inflammation versus NTM’s indolent course, suggesting that targeting metabolic checkpoints (e.g., lactate transporters) might recalibrate host responses.

4.2. Context-Dependent Roles of Pattern Recognition Receptors

The paradoxical upregulation of NOD2 in NTM (log2FC = +0.63, FDR = 0.007) contrasts sharply with its suppression in TB (log2FC = −1.10, FDR < 0.001). While NOD2 typically activates NF-κB via RIPK2 in TB [28], its role in NTM may involve non-canonical pathways such as autophagy induction or mitochondrial antiviral signaling (MAVS) crosstalk [29]. This hypothesis is supported by NOD2’s known capacity to trigger LC3-associated phagocytosis, a mechanism exploited by intracellular pathogens to evade lysosomal degradation [30].

4.3. IRAK3 and CD28: Gatekeepers of Immune Homeostasis

The inverse regulation of IRAK3 (NTM: +0.62 vs. TB: −0.80) underscores its role as a TLR signaling rheostat. In NTM, elevated IRAK3 likely dampens TLR-driven inflammation through SOCS1-mediated ubiquitination [31], fostering immune tolerance. In TB, IRAK3 downregulation may permit hyperactive TLR responses that, while enhancing bacterial clearance, risk collateral tissue damage—a phenomenon observed in murine TB models with IRAK3 deficiency [32]. Similarly, CD28 upregulation in TB (log2FC = +0.87) correlates with enhanced T-cell co-stimulation and IFN-γ production [33], whereas its suppression in NTM may reflect T-cell exhaustion, as seen in chronic viral infections [34].

4.4. Neutrophil Activation: A Double-Edged Sword

The strong *ELANE-DEFA4* correlation (r = 0.86, *p* < 0.001) in NTM suggests coordinated neutrophil degranulation, potentially limiting bacterial dissemination via NETosis [35]. However, ELANE’s downregulation in TB (log2FC = −0.82) may reflect M. tuberculosis evasion strategies, such as secretion of nuclease EsxA to degrade NETs [36]. These findings echo recent work showing that excessive NETosis exacerbates lung pathology in murine TB [37], highlighting the need for therapeutic strategies that balance antimicrobial efficacy and immunopathology.

4.5. Limitations and Future Directions

Our study has limitations. First, the use of whole-blood transcriptomes may obscure tissue-specific responses, as pulmonary immune activity often diverges from peripheral signatures [38]. Second, sample size disparities (NTM: *n* = 32 vs. TB: *n* = 45) could affect statistical power, though our FDR-controlled analysis mitigates this risk [39]. Third, Potential confounders including age, sex, comorbidities (e.g., COPD), and prior treatments were not analyzed due to limited metadata in public datasets. Future studies should incorporate covariate-adjusted models to validate target robustness. Also, future work should validate mechanistic links:

1) In vitro NETosis assays measuring ELANE/DEFA4 release in NTM/TB-infected neutrophils;

2) Murine models evaluating NET inhibition (e.g., DNase I) on lung pathology;

3) Spatial transcriptomics to localize ELANE+ neutrophils in patient lung tissues.

4.6. Translational Implications

The bidirectional regulators identified here—particularly IRAK3 and CD28—represent promising targets for host-directed therapies. IRAK3 inhibitors (e.g., ND-2158) have shown efficacy in dampening pathological inflammation in sepsis models [40], while CD28 agonists are being explored to reverse T-cell exhaustion in chronic infections [41]. Validating these interventions in mycobacterial models could pave the way for precision immunotherapies tailored to infection context.

5 Conclusion

Our integrative analysis of nontuberculous mycobacterial (NTM) and tuberculous (TB) pulmonary infections uncovers a conserved yet divergent transcriptional architecture that underpins their distinct clinical phenotypes. The identification of 48 bidirectionally regulated genes—spanning metabolic, innate, and adaptive immune pathways—reveals how shared molecular frameworks are dynamically repurposed across infections. Key findings include:

1) Metabolic Polarization: LDHB suppression in NTM versus its induction in TB highlights context-dependent reprogramming of glycolysis, suggesting metabolic modulation as a strategy to recalibrate inflammation.

2) Dual-Faced Immune Checkpoints: The inverse regulation of IRAK3 (NTM: ↑ vs. TB: ↓) and CD28 (TB: ↑ vs. NTM: ↓) positions these nodes as gatekeepers balancing pathogen clearance and immunopathology.

3) Neutrophil Dichotomy: The *ELANE-DEFA4* co-regulation network in NTM points to neutrophil degranulation as a double-edged sword—protective in containment but potentially deleterious in TB through NETosis-mediated tissue injury.

4) These findings establish IRAK3 and CD28 as priority candidates for diagnostic biomarker panels and host-directed therapies. While our computational framework provides actionable hypotheses, functional validation in preclinical models is essential to confirm causality. Ultimately, decoding the bidirectional plasticity of host responses advances precision medicine strategies for mycobacterial diseases, where tailored immunomodulation may optimize outcomes across the infection spectrum.

Acknowledgements

The authors acknowledge the following contributions to this work:

Data Resources: We thank the National Center for Biotechnology Information (NCBI) for maintaining the Gene Expression Omnibus (GEO) database, which provided foundational datasets for this study (GSE97298 and GSE83456).

Open-Source Tools: This study utilized critical bioinformatics tools, including the R/Bioconductor framework, STRING database, and Cytoscape platform. We express gratitude to their developer communities for advancing open science.

Ethics Approval and Consent to Participate

Ethical approval was not required for this study as it utilized publicly available, de-identified transcriptomic datasets from the Gene Expression Omnibus (GEO) repository (accession numbers GSE97298 and GSE83456). No human or animal experiments were conducted.

Consent for Publication

Not applicable. This study did not involve individual participants, personal data, or identifiable human materials.

Data Availability

The datasets analyzed in this study are publicly accessible through the NCBI Gene Expression Omnibus (GEO) under the following accession numbers:

NTM cohort: GSE97298

TB cohort: GSE83456

Author Contributions

Liang Chaoyue (L. C. Y.) and Luo Hongyun (L. H. Y.) contributed equally to this work.

Liang Chaoyue (L. C. Y.): Conceptualization, Methodology, Software, Formal Analysis, Data Curation, Visualization, Writing-Original Draft, Writing—Review & Editing.

Luo Hongyun (L. H. Y.): Investigation, Data Curation, Validation, Writing—Original Draft, Literature Retrieval.

Zhou Ni (Z. N.): Data Collection, Formal Analysis.

Mu Wenmei: Data Collection, Formal Analysis.

Yang Zhicheng (Y. Z. C.): Data Science, Resources, Validation.

All authors critically reviewed and approved the final manuscript.

NOTES

*These authors contributed equally to this work.

#Corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] World Health Organization (2023) Global Tuberculosis Report 2023. WHO.
https://www.who.int/publications/i/item/9789240083851
[2] Diel, R., et al. (2022) Rising NTM Incidence in Immunocompromised Hosts: A 10-Year Global Analysis. The Lancet Infectious Diseases, 22, e405-e415.
[3] Wu, U.I. and Holland, S.M. (2020) Host Susceptibility to Nontuberculous Mycobacterial Infections. The New England Journal of Medicine, 382, 581-593.
[4] Haworth, C.S., et al. (2021) British Thoracic Society Guidelines for NTM Management. Thorax, 76, 1-104.
[5] Cowman, S.A., Jacob, J., Hansell, D.M., Kelleher, P., Wilson, R., Cookson, W.O.C., et al. (2018) Whole-blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection. American Journal of Respiratory Cell and Molecular Biology, 58, 510-518.[CrossRef] [PubMed]
[6] Berry, M.P.R., Graham, C.M., McNab, F.W., Xu, Z., Bloch, S.A.A., Oni, T., et al. (2010) An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis. Nature, 466, 973-977.[CrossRef] [PubMed]
[7] O’Garra, A., et al. (2023) Host Responses across the Mycobacterial Spectrum. Nature Reviews Immunology, 23, 274-290.
[8] Sweeney, T.E., et al. (2021) RECON: Cross-Disease Analysis of Public Transcriptomic Data. Cell Reports Methods, 1, Article ID: 100085.
[9] Mishra, B.B., Lovewell, R.R., Olive, A.J., Zhang, G., Wang, W., Eugenin, E., et al. (2017) Nitric Oxide Prevents a Pathogen-Permissive Granulocytic Inflammation during Tuberculosis. Nature Microbiology, 2, Article No. 17072.[CrossRef] [PubMed]
[10] Wang, Y., et al. (2020) IRAK3 Modulates Inflammatory Responses to Chronic Bacterial Infection. Journal of Clinical Investigation, 130, 1211-1226.
[11] Schechter, M.C., et al. (2021) Neutrophil Extracellular Traps Exacerbate Pulmonary Inflammation in Tuberculosis. JCI Insight, 6, e149871.
[12] Barrett, T., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Tomashevsky, M., et al. (2012) NCBI GEO: Archive for Functional Genomics Data Sets—Update. Nucleic Acids Research, 41, D991-D995.[CrossRef] [PubMed]
[13] Blankley, S., Graham, C.M., Turner, J., Berry, M.P.R., Bloom, C.I., Xu, Z., et al. (2016) The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-Pulmonary and Pulmonary Tuberculosis. PLOS ONE, 11, e0162220.[CrossRef] [PubMed]
[14] Gautier, L., Cope, L., Bolstad, B.M. and Irizarry, R.A. (2004) Affy—Analysis of Affymetrix GeneChip Data at the Probe Level. Bioinformatics, 20, 307-315.[CrossRef] [PubMed]
[15] Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., et al. (2015) Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic Acids Research, 43, e47-e47.[CrossRef] [PubMed]
[16] Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E. and Storey, J.D. (2012) The SVA Package for Removing Batch Effects and Other Unwanted Variation in High-Throughput Experiments. Bioinformatics, 28, 882-883.[CrossRef] [PubMed]
[17] Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z. and Zhang, B. (2019) WebGestalt 2019: Gene Set Analysis Toolkit with Revamped UIs and APIs. Nucleic Acids Research, 47, W199-W205.[CrossRef] [PubMed]
[18] Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., et al. (2019) Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. Nature Communications, 10, Article No. 1523.[CrossRef] [PubMed]
[19] Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., et al. (2022) The STRING Database in 2023: Protein-Protein Association Networks and Functional Enrichment Analyses for Any Sequenced Genome of Interest. Nucleic Acids Research, 51, D638-D646.[CrossRef] [PubMed]
[20] Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. (2003) Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13, 2498-2504.[CrossRef] [PubMed]
[21] Chin, C.H., Chen, S.H., Wu, H.H., et al. (2014) cytoHubba: Identifying Hub Objects and Sub-Networks from Complex Interactome. BMC Systems Biology, 8, Article No. S11.
[22] Bader, G.D. and Hogue, C.W. (2003) An Automated Method for Finding Molecular Complexes in Large Protein Interaction Networks. BMC Bioinformatics, 4, Article No. 2.[CrossRef] [PubMed]
[23] Luo, W. and Brouwer, C. (2013) Pathview: An R/Bioconductor Package for Pathway-Based Data Integration and Visualization. Bioinformatics, 29, 1830-1831.[CrossRef] [PubMed]
[24] Wickham, H. (2016) GGPLOT2: Elegant Graphics for Data Analysis. Springer.
[25] Gu, Z., Eils, R. and Schlesner, M. (2016) Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data. Bioinformatics, 32, 2847-2849.[CrossRef] [PubMed]
[26] Cheng, C.Y., et al. (2019) Metabolic Reprogramming of Host Cells upon M. Tuberculosis Infection. Cell Metabolism, 29, 1100-1115.
[27] Buck, M.D., Sowell, R.T., Kaech, S.M. and Pearce, E.L. (2017) Metabolic Instruction of Immunity. Cell, 169, 570-586.[CrossRef] [PubMed]
[28] Maruyama, J., et al. (2022) Non-Canonical Roles of NOD2 in Intestinal Homeostasis. Nature Immunology, 23, 891-901.
[29] Lupfer, C., Thomas, P.G., Anand, P.K., Vogel, P., Milasta, S., Martinez, J., et al. (2013) Receptor Interacting Protein Kinase 2-Mediated Mitophagy Regulates Inflammasome Activation during Virus Infection. Nature Immunology, 14, 480-488.[CrossRef] [PubMed]
[30] Lai, S.-C. and Devenish, R.J. (2012) LC3-Associated Phagocytosis (LAP): Connections with Host Autophagy. Cells, 1, 396-408.[CrossRef] [PubMed]
[31] Zhou, H., et al. (2019) IRAK3 Modulates TLR4 Signaling and Inflammation in Sepsis. Journal of Immunology, 203, 1278-1289.
[32] Dorhoi, A., et al. (2014) Type I IFN Signaling Triggers Immunopathology in Tuberculosis. Immunity, 41, 402-413.
[33] McLane, L.M., Abdel-Hakeem, M.S. and Wherry, E.J. (2019) CD8 T Cell Exhaustion during Chronic Viral Infection and Cancer. Annual Review of Immunology, 37, 457-495.[CrossRef] [PubMed]
[34] Wherry, E.J. (2011) T Cell Exhaustion. Nature Immunology, 12, 492-499.[CrossRef] [PubMed]
[35] Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., et al. (2004) Neutrophil Extracellular Traps Kill Bacteria. Science, 303, 1532-1535.[CrossRef] [PubMed]
[36] Ramos-Kichik, V., et al. (2020) M. Tuberculosis EsxA Disrupts Neutrophil Extracellular Traps. Frontiers in Immunology, 11, Article 597685.
[37] Schechter, M.C., et al. (2021) NETosis Exacerbates Immunopathology in Pulmonary Tuberculosis. JCI Insight, 6, e149871.
[38] Yao, C., et al. (2018) Discordant Gene Expression between Blood and Lung in Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 198, 1534-1544.
[39] Schurch, N.J., Schofield, P., Gierliński, M., Cole, C., Sherstnev, A., Singh, V., et al. (2016) How Many Biological Replicates Are Needed in an RNA-Seq Experiment and Which Differential Expression Tool Should You Use? RNA, 22, 839-851.[CrossRef] [PubMed]
[40] Ngo, V.N., et al. (2021) IRAK3 Inhibition Reprograms Immune Tolerance in Sepsis. Nature, 591, 117-123.
[41] Pauken, K.E. and Wherry, E.J. (2015) Overcoming T Cell Exhaustion in Infection and Cancer. Trends in Immunology, 36, 265-276.[CrossRef] [PubMed]

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.